Cargando…
Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients
PURPOSE/METHODS: The determination of tumour biomarkers is paramount to advancing personalized medicine, more so in rare tumours like medullary thyroid carcinoma (MTC), whose diagnosis is still challenging. The aim of this study was to identify non-invasive circulating biomarkers in MTC. To achieve...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632281/ https://www.ncbi.nlm.nih.gov/pubmed/37286863 http://dx.doi.org/10.1007/s40618-023-02115-2 |
_version_ | 1785146130868207616 |
---|---|
author | Besharat, Z. M. Trocchianesi, S. Verrienti, A. Ciampi, R. Cantara, S. Romei, C. Sabato, C. Noviello, T. M. R. Po, A. Citarella, A. Caruso, F. P. Panariello, I. Gianno, F. Carpino, G. Gaudio, E. Chiacchiarini, M. Masuelli, L. Sponziello, M. Pecce, V. Ramone, T. Maino, F. Dotta, F. Ceccarelli, M. Pezzullo, L. Durante, C. Castagna, M. G. Elisei, R. Ferretti, E. |
author_facet | Besharat, Z. M. Trocchianesi, S. Verrienti, A. Ciampi, R. Cantara, S. Romei, C. Sabato, C. Noviello, T. M. R. Po, A. Citarella, A. Caruso, F. P. Panariello, I. Gianno, F. Carpino, G. Gaudio, E. Chiacchiarini, M. Masuelli, L. Sponziello, M. Pecce, V. Ramone, T. Maino, F. Dotta, F. Ceccarelli, M. Pezzullo, L. Durante, C. Castagna, M. G. Elisei, R. Ferretti, E. |
author_sort | Besharat, Z. M. |
collection | PubMed |
description | PURPOSE/METHODS: The determination of tumour biomarkers is paramount to advancing personalized medicine, more so in rare tumours like medullary thyroid carcinoma (MTC), whose diagnosis is still challenging. The aim of this study was to identify non-invasive circulating biomarkers in MTC. To achieve this goal, paired MTC tissue and plasma extracellular vesicle samples were collected from multiple centres and microRNA (miRNA) expression levels were evaluated. RESULTS: The samples from a discovery cohort of 23 MTC patients were analysed using miRNA arrays. Lasso logistic regression analysis resulted in the identification of a set of circulating miRNAs as diagnostic biomarkers. Among them, miR-26b-5p and miR-451a, were highly expressed and their expression decreased during follow-up in disease-free patients in the discovery cohort. Circulating miR-26b-5p and miR-451a were validated using droplet digital PCR in a second independent cohort of 12 MTC patients. CONCLUSION: This study allowed the identification and validation of a signature of two circulating miRNAs, miR-26b-5p and miR-451a, in two independent cohorts reporting a significant diagnostic performance for MTC. The results of this study offer advancements in molecular diagnosis of MTC proposing a novel non-invasive tool to use in precision medicine. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40618-023-02115-2. |
format | Online Article Text |
id | pubmed-10632281 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-106322812023-11-14 Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients Besharat, Z. M. Trocchianesi, S. Verrienti, A. Ciampi, R. Cantara, S. Romei, C. Sabato, C. Noviello, T. M. R. Po, A. Citarella, A. Caruso, F. P. Panariello, I. Gianno, F. Carpino, G. Gaudio, E. Chiacchiarini, M. Masuelli, L. Sponziello, M. Pecce, V. Ramone, T. Maino, F. Dotta, F. Ceccarelli, M. Pezzullo, L. Durante, C. Castagna, M. G. Elisei, R. Ferretti, E. J Endocrinol Invest Original Article PURPOSE/METHODS: The determination of tumour biomarkers is paramount to advancing personalized medicine, more so in rare tumours like medullary thyroid carcinoma (MTC), whose diagnosis is still challenging. The aim of this study was to identify non-invasive circulating biomarkers in MTC. To achieve this goal, paired MTC tissue and plasma extracellular vesicle samples were collected from multiple centres and microRNA (miRNA) expression levels were evaluated. RESULTS: The samples from a discovery cohort of 23 MTC patients were analysed using miRNA arrays. Lasso logistic regression analysis resulted in the identification of a set of circulating miRNAs as diagnostic biomarkers. Among them, miR-26b-5p and miR-451a, were highly expressed and their expression decreased during follow-up in disease-free patients in the discovery cohort. Circulating miR-26b-5p and miR-451a were validated using droplet digital PCR in a second independent cohort of 12 MTC patients. CONCLUSION: This study allowed the identification and validation of a signature of two circulating miRNAs, miR-26b-5p and miR-451a, in two independent cohorts reporting a significant diagnostic performance for MTC. The results of this study offer advancements in molecular diagnosis of MTC proposing a novel non-invasive tool to use in precision medicine. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40618-023-02115-2. Springer International Publishing 2023-06-07 2023 /pmc/articles/PMC10632281/ /pubmed/37286863 http://dx.doi.org/10.1007/s40618-023-02115-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Besharat, Z. M. Trocchianesi, S. Verrienti, A. Ciampi, R. Cantara, S. Romei, C. Sabato, C. Noviello, T. M. R. Po, A. Citarella, A. Caruso, F. P. Panariello, I. Gianno, F. Carpino, G. Gaudio, E. Chiacchiarini, M. Masuelli, L. Sponziello, M. Pecce, V. Ramone, T. Maino, F. Dotta, F. Ceccarelli, M. Pezzullo, L. Durante, C. Castagna, M. G. Elisei, R. Ferretti, E. Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients |
title | Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients |
title_full | Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients |
title_fullStr | Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients |
title_full_unstemmed | Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients |
title_short | Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients |
title_sort | circulating mir-26b-5p and mir-451a as diagnostic biomarkers in medullary thyroid carcinoma patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632281/ https://www.ncbi.nlm.nih.gov/pubmed/37286863 http://dx.doi.org/10.1007/s40618-023-02115-2 |
work_keys_str_mv | AT besharatzm circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT trocchianesis circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT verrientia circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT ciampir circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT cantaras circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT romeic circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT sabatoc circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT noviellotmr circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT poa circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT citarellaa circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT carusofp circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT panarielloi circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT giannof circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT carpinog circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT gaudioe circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT chiacchiarinim circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT masuellil circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT sponziellom circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT peccev circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT ramonet circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT mainof circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT dottaf circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT ceccarellim circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT pezzullol circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT durantec circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT castagnamg circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT eliseir circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients AT ferrettie circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients |